Sign In
Buy AUTL
$1.62
-0.130 (-7.43%)
At Close: Jun 03, 2026
Autolus Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on March 27, 2026
04:10pm, Monday, 16'th Mar 2026
LONDON and GAITHERSBURG, Md., March 16, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial stage biopharmaceutical company developing, manufacturing and delivering next-gen
Autolus Therapeutics Touts $75M Year-1 Obe-cel Launch, Sees $120M-$135M Revenue in 2026
02:32am, Thursday, 05'th Mar 2026
Autolus Therapeutics (NASDAQ: AUTL) Chief Executive Officer Christian Itin told conference attendees the company is entering its second year as a commercial-stage business following the launch of its
Autolus Therapeutics to Participate in Upcoming Investor Conferences
07:00am, Tuesday, 24'th Feb 2026
LONDON and GAITHERSBURG, Md., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-gene
Stock Traders Purchase Large Volume of Autolus Therapeutics Call Options (NASDAQ:AUTL)
01:12am, Tuesday, 24'th Feb 2026
Autolus Therapeutics PLC Sponsored ADR (NASDAQ: AUTL - Get Free Report) saw unusually large options trading activity on Monday. Stock traders acquired 2,496 call options on the stock. This is an incre
Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL) Receives $8.33 Average Target Price from Brokerages
01:46am, Tuesday, 10'th Feb 2026
Autolus Therapeutics PLC Sponsored ADR (NASDAQ: AUTL - Get Free Report) has been assigned a consensus rating of "Hold" from the six analysts that are covering the firm, MarketBeat reports. Two researc
Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
08:57am, Wednesday, 04'th Feb 2026
LONDON and GAITHERSBURG, Md., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-gene
New Strong Sell Stocks for January 30th
07:10am, Friday, 30'th Jan 2026
TSE, PAC and AUTL have been added to the Zacks Rank #5 (Strong Sell) List on January 30th, 2026.
New Strong Sell Stocks for January 22nd
07:05am, Thursday, 22'nd Jan 2026
MHVYF, NFG and AUTL have been added to the Zacks Rank #5 (Strong Sell) List on January 22, 2026.
Company expects preliminary unaudited AUCATZYL® net product revenue of approximately $24 million for the fourth quarter of 2025 and approximately $75 million for the full year of 2025 Autolus anticip
Autolus Therapeutics to Evaluate Automated Manufacturing of AUCATZYL® (obe-cel) on the Cellares Cell ShuttleTM Platform
09:00am, Tuesday, 06'th Jan 2026
SOUTH SAN FRANCISCO, Calif. & LONDON--(BUSINESS WIRE)--Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation pr
Autolus Therapeutics to Evaluate Automated Manufacturing of AUCATZYL® (obe-cel) on the Cellares Cell Shuttle™ Platform
09:00am, Tuesday, 06'th Jan 2026
SOUTH SAN FRANCISCO, Calif. and LONDON, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering
Perpetual Ltd Has $784,000 Position in Autolus Therapeutics PLC Sponsored ADR $AUTL
05:40am, Monday, 22'nd Dec 2025
Perpetual Ltd lessened its holdings in shares of Autolus Therapeutics PLC Sponsored ADR (NASDAQ: AUTL) by 42.0% in the undefined quarter, according to its most recent filing with the SEC. The fund own
Autolus presented preliminary data from the Phase 1 CARLYSLE trial in patients with severe refractory systemic lupus erythematosus (srSLE) at ASH 2025.
Obe-cel demonstrates high remission rates in pediatric patients with high-risk r/r B-ALL with overall response rate (ORR) of 95.5%; low rates of high-grade cytokine release syndrome (CRS) and immune e
Cetera Investment Advisers Has $1.41 Million Position in Autolus Therapeutics PLC Sponsored ADR $AUTL
04:14am, Tuesday, 02'nd Dec 2025
Cetera Investment Advisers raised its position in Autolus Therapeutics PLC Sponsored ADR (NASDAQ: AUTL) by 17.6% in the undefined quarter, according to its most recent Form 13F filing with the SEC. Th
